CN100425241C - 由Rho激酶抑制剂和前列腺素类物质构成的青光眼治疗剂 - Google Patents

由Rho激酶抑制剂和前列腺素类物质构成的青光眼治疗剂 Download PDF

Info

Publication number
CN100425241C
CN100425241C CNB038233029A CN03823302A CN100425241C CN 100425241 C CN100425241 C CN 100425241C CN B038233029 A CNB038233029 A CN B038233029A CN 03823302 A CN03823302 A CN 03823302A CN 100425241 C CN100425241 C CN 100425241C
Authority
CN
China
Prior art keywords
kinases
prostaglandins
glaucoma
rho inhibitors
rho
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038233029A
Other languages
English (en)
Other versions
CN1684689A (zh
Inventor
中岛正
松木雄
原英彰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of CN1684689A publication Critical patent/CN1684689A/zh
Application granted granted Critical
Publication of CN100425241C publication Critical patent/CN100425241C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

本发明提供一种Rho激酶抑制剂和前列腺素类物质组合得到的有效的青光眼治疗剂。通过将Rho激酶抑制剂和前列腺素类物质组合可以使其各自的降低眼压的作用相互补充和/或增强。给药方式可以为并用给药，也可以制成合剂给药。

Description

由Rho激酶抑制剂和前列腺素类物质构成的青光眼治疗剂
技术领域
本发明涉及由Rho激酶抑制剂和前列腺素类物质组合构成的青光眼治疗剂。
背景技术
青光眼是一种由各种病因引起眼压升高、眼球内部组织(视网膜、视神经等)受到损害而导致的有致盲危险性的难治性眼科疾病。青光眼的治疗方法一般为降低眼压疗法，代表性的疗法有药物疗法、激光疗法、手术疗法等。
药物疗法中使用交感神经激动剂(肾上腺素等非选择性激动剂、阿可乐定(apraclonidine)等α2激动剂)、交感神经阻断剂(噻吗洛尔、苯呋洛尔等β阻断剂、盐酸布那唑嗪等α1阻断剂)、副交感神经兴奋剂(匹鲁卡品等)、碳酸脱水酶抑制剂(乙酰唑胺等)、前列腺素类(乌诺前列酮异丙酯、拉坦前列素、曲伏前列素、比马前列胺)等药物。
最近，作为基于新型作用机理的青光眼治疗药开发了Rho激酶抑制剂(国际公开WO00/09162号)。非专利文献1公开了Rho激酶抑制剂通过促进经由小梁网的房水流出以降低眼压，IOVS，42(1)，137-144(2001)、IOVS，42(5)，1029-1037(2001)中进一步公开了其作用机理为小梁细胞的细胞骨架的重新构建。
此前研究并报道了将具有降低眼压作用的药物相互组合使用以治疗青光眼。例如，日本专利2726672号公报报道了将交感神经阻断剂和前列腺素类物质组合进行给药的方法。另外，国际公开WO 02/38158号公开了将具有降低眼压作用的几种药物组合对眼睛给药以治疗青光眼的方法。
但是，所有报道都没有关于Rho激酶抑制剂的记载，当然也没有关于其与前列腺素类物质并用效果的记载。
如上所述，目前为止，完全没有关于将Rho激酶抑制剂与前列腺素类物质组合时的青光眼治疗效果的研究和报道。
发明内容
研究Rho激酶抑制剂和前列腺素类物质组合制成的青光眼治疗剂的效用是一个非常有趣的课题。
本发明人等深入地研究了将Rho激酶抑制剂和前列腺素类物质组合产生的效果，结果发现，将上述药物组合使用与各药物单独使用时相比，眼压降低作用有所增强和/或作用的持续性有所提高，从而完成了本发明。详细的试验方法和结果在后述的药理试验项中进行说明，可以看出通过将Rho激酶抑制剂和前列腺素类物质相互组合，可以使眼压降低作用显著增强和/或作用的持续性显著提高。
本发明为一种青光眼治疗剂，是将Rho激酶抑制剂和前列腺素类物质组合制成的，所述成分可相互补充和/或增强其治疗作用。
给药方式可以为Rho激酶抑制剂和前列腺素类物质以各自的制剂形式给药，即合并给药；也可以将它们制成1种制剂给药、即以合剂的形式给药。
本发明中所述的Rho激酶抑制剂和前列腺素类物质也包括盐的形态。上述化合物含有氨基等碱性基团时，也可以与盐酸、硝酸等无机酸成盐，或者与草酸、琥珀酸、醋酸等有机酸成盐；含有羧基等酸性基团时，也可以与钠、钾等碱金属成盐，或与钙等碱土类金属成盐。
另外，本发明中所述的Rho激酶抑制剂和前列腺素类物质也包括酯类等衍生物。酯类具体可以举出例如甲基酯、乙基酯、异丙基酯等烷基酯。
本发明的特征为将Rho激酶抑制剂和前列腺素类物质组合使用以治疗青光眼。
本发明中所述的Rho激酶抑制剂是指阻断随着Rho活化而被活化的丝氨酸/苏氨酸激酶的化合物。例如可以举出阻断ROKα(ROCK-II)、p160ROCK(ROKβ、ROCK-I)及其它具有丝氨酸/苏氨酸激酶活性的蛋白质的化合物。Rho激酶抑制剂具体可以举出WO 98/06433、WO 00/09162中公开的(R)-反式-N-(吡啶-4-基)-4-(1-氨基乙基)环己烷羧酰胺、(R)-(+)-N-(1H-吡咯并[2，3-b]吡啶-4-基)-4-(1-氨基乙基)苯酰胺等Rho激酶抑制剂；或者WO 97/23222、Nature，389，990-994(1997)中公开的1-(5-异喹啉磺酰基)高哌嗪、1-(5-异喹啉磺酰基)-2-甲基哌嗪等Rho激酶抑制剂；WO 01/56988中公开的(1-苄基吡咯烷-3-基)-(1H-吲唑-5-基)胺等Rho激酶抑制剂；WO 02/100833中公开的(1-苄基哌啶-4-基)-(1H-吲唑-5-基)胺等Rho激酶抑制剂；WO 02/076976中公开的N-[2-(4-氟苯基)-6，7-二甲氧基-4-喹唑啉基]-N-(1H-吲唑-5-基)胺等Rho激酶抑制剂；WO 02/076977中公开的N-4-(1H-吲唑-5-基)-6，7-二甲氧基-N-2-吡啶-4-基-喹唑啉-2，4-二胺等Rho激酶抑制剂；WO 99/64011中公开的4-甲基-5-(2-甲基-[1，4]苯甲二氮卓一1-磺酰基)异喹啉等Rho激酶抑制剂。
前列腺素类物质只要是具有降低眼压的作用并对治疗青光眼有效的前列腺素类物质即可。具有降低眼压作用的前列腺素类具体可以举出，特开昭59-1418中公开的前列腺素类物质(特别是前列腺素F2α之类的天然前列腺素)、特表平3-501025中公开的拉坦前列素等前列腺素类物质、特开平2-108中公开的乌诺前列酮异丙酯等前列腺素类物质、特表平8-501310中公开的比马前列素(Bimatoprost)等前列腺素类物质、特开平10-182465中公开的曲伏前列素(Travoprost)等前列腺素类物质等，特别优选使用已作为青光眼治疗剂出售的拉坦前列素、乌诺前列酮异丙酯、比马前列素(Bimatoprost)、曲伏前列素(Travoprost)。
本发明中所述的青光眼有原发性开角型青光眼、正常眼压青光眼、房水产生过多型青光眼、高眼压症、急性闭角型青光眼、慢性闭角型青光眼、混合型青光眼、类固醇性青光眼、淀粉样变性(amyloid)青光眼、新生血管性青光眼、恶性青光眼、水晶体的囊性青光眼、虹膜高褶型青光眼(plateau-iris syndrome)等。
作为实施本发明的制剂，可以是将Rho激酶抑制剂和前列腺素类物质各自配方的2种制剂，也可以为配合了各成分的1种制剂。上述制剂化不需要特殊的技术，可以利用广泛采用的技术进行制剂化。给药方式优选眼局部给药，剂型优选滴眼剂或眼软膏。
将Rho激酶抑制剂和前列腺素类物质分别制剂化时，可以依照各种公知的方法进行配制。例如Rho激酶抑制剂的制剂可以参照上述国际公开专利公报(WO 00/09162、WO 97/23222)中记载的制剂例进行配制。前列腺素类物质的制剂可以参照上述日本公开专利公报或者日本公表专利公报(特开昭59-1418、特表平3-501025、特开平2-108、特表平8-501310、特开平10-182465)中记载的制剂例进行配制，特别是也可以使用已经作为青光眼治疗剂出售的拉坦前列素、乌诺前列酮异丙酯、比马前列素、曲伏前列素等市售制剂。
Rho激酶抑制剂和前列腺素类物质二者配合的制剂也可以按照公知的方法进行配制。例如滴眼剂，可以根据需要使用氯化钠、浓甘油等等渗剂；磷酸钠、醋酸钠等缓冲剂；聚氧乙烯脱水山梨醇单油酸酯、硬脂酸聚烃氧40酯、聚氧乙烯硬化蓖麻油等表面活性剂；枸橼酸钠、乙二胺四乙酸钠等稳定剂；苯扎氯胺、对羟基苯甲酸酯等防腐剂等进行配制。pH只要在眼科制剂所允许的范围内即可，优选pH在4～8的范围内。在后述的实施例项中记载了一部分制剂例作为参考，但本发明的范围并不受限于后述制剂例。
Rho激酶抑制剂及前列腺素类物质的给药量可以根据患者的症状、年龄、剂型、给药途径等进行决定。下面以滴眼给药为例进行简单说明。Rho激酶抑制剂的给药量因药物的种类而不同，通常1日给药量在0.025～10000μg的范围内，可以每日给药1次，也可以分数次给药，用量可以根据患者的年龄、症状等进行适当的增减。
前列腺素类物质的给药量因药物的种类而不同，通常1日给药量在0.1～1000μg的范围内，可在1日内1次或分数次给药。具体而言，拉坦前列素通常使用的1日剂量为1～5μg、乌诺前列酮异丙酯通常使用的1日剂量为30～300μg，上述用量可以根据患者的年龄、症状等进行适当的增减。另外，其它前列腺素类物质也可以基于同样的标准决定其用量。
上述给药量也适合将Rho激酶抑制剂与前列腺素类物质并用给药的情况，但在使用Rho激酶抑制剂和前列腺素类物质二者配合制得的制剂进行给药时，配制出适当地选择了配合比例的制剂，使1日给药量为上述各成分的用量或其以下，将该配合制剂1日1次或分数次给药。
附图说明
图1为表示各给药组眼压经时变化的曲线图。其中眼压以从初期眼压开始的变化值表示。□为化合物A和乌诺前列酮异丙酯并用的给药组，■为化合物A单独给药组，△为乌诺前列酮异丙酯单独给药组，○为对照组。
图2为表示各给药组眼压经时变化的曲线图。其中眼压以从初期眼压开始的变化值表示。□为化合物B和乌诺前列酮异丙酯并用的给药组，■为化合物B单独给药组，△为乌诺前列酮异丙酯单独给药组，○为对照组。
图3为表示各给药组眼压经时变化的曲线图。其中眼压以从初期眼压开始的变化值表示。□为化合物A和拉坦前列素并用的给药组，■为化合物A单独给药组，△为拉坦前列素单独给药组，○为对照组。
图4为表示各给药组眼压经时变化的曲线图。其中眼压以从初期眼压开始的变化值表示。□为化合物B和拉坦前列素并用的给药组，■为化合物B单独给药组，△为拉坦前列素单独给药组，○为对照组。
具体实施方式
以下以制剂例和药理试验作为实施例进行说明，其目的是为了更加好的理解本发明，并不能限定本发明的范围。
实施例
[制剂例]
以下说明本发明中配合了Rho激酶抑制剂((R)-(+)-N-(1H-吡咯并[2，3-b]吡啶-4-基)-4-(1-氨基乙基)苯酰胺二盐酸盐)和前列腺素类物质(乌诺前列酮异丙酯)的滴眼剂的普通制剂例。
滴眼剂(100ml中)
(R)-(+)-N-(1H-吡咯并[2，3-b]吡啶-4-基)-4-
(1-氨基乙基)苯酰胺二盐酸盐        0.3g
乌诺前列酮异丙酯                  0.06g
硼酸                              0.2g
浓甘油                            0.25g
苯扎氯胺                          0.005g
稀盐酸                            适量
氢氧化钠                          适量
蒸馏水                            适量
可改变上述配方中Rho激酶抑制剂和前列腺素类物质的种类及配合量，并且适当改变添加剂的用量，以配制出所需组成及所需浓度的滴眼液。
[药理试验]
为了检验Rho激酶抑制剂和前列腺素类物质组合的有效性，研究了将Rho激酶抑制剂和前列腺素类物质并用对日本白色家兔(种系：JW，性别：雄性)或食蟹猴(性别：雄性)进行给药后的眼压降低效果。Rho激酶抑制剂使用(R)-(+)-N-(1H-吡咯并[2，3-b]吡啶-4-基)-4-(1-氨基乙基)苯酰胺二盐酸盐[化合物A]或者1-(5-异喹啉磺酰基)高哌嗪二盐酸盐[化合物B]，前列腺素类物质使用乌诺前列酮异丙酯或者拉坦前列素。
(试验化合物溶液的配制)
1.Rho激酶抑制剂溶液的配制
将Rho激酶抑制剂溶解于生理盐水之后，加入氢氧化钠来中和溶液(pH6.0～7.0)，从而配制出所需浓度的Rho激酶抑制剂溶液。
2.前列腺素类物质溶液的配制
直接使用市售的乌诺前列酮异丙酯滴眼液(商品名：Rescula滴眼液)或者拉坦前列素滴眼液(商品名：Xalatan滴眼液)，或者用生理盐水稀释，配制出所需浓度的前列腺素类物质溶液。
(试验方法)
以下研究了Rho激酶抑制剂和前列腺素类物质并用给药时的眼压降低效果。为了比较对照，也研究了Rho激酶抑制剂单独给药或者前列腺素类物质单独给药时的眼压降低效果。对照组中只给予基液(生理盐水)。试验动物使用日本白色家兔(种系：JW，性别：雄性)或者食蟹猴(性别：雄性)。
(给药方法及测定方法)
1.Rho激酶抑制剂和前列腺素类物质并用给药
1)给试验动物的双眼各点1滴0.4％盐酸羟丁普鲁卡因进行局部麻醉。
2)在临给予试验化合物之前测定眼压，作为初期眼压。
3)用Rho激酶抑制剂溶液对试验动物的一只眼滴眼给药(对侧眼不作处理)。由于不能同时以前列腺素类物质溶液进行滴眼给药，因而间隔少许时间(约5分钟)后对同一只眼进行前列腺素类物质溶液的滴眼给药。
4)在点眼给予Rho激酶抑制剂溶液后的2小时、4小时、6小时及8小时后分别对两眼点以1滴0.4％盐酸羟丁普鲁卡因进行局部麻醉后，测定眼压。眼压测定3次，其平均值在结果中示出。
需要说明的是，下述试验例中的试验2测定了2小时、4小时及6小时后的眼压。
2.Rho激酶抑制剂单独给药
用生理盐水代替前列腺素类物质溶液，除此之外，用与上述并用给药试验同样的方法进行试验。
3.前列腺素类物质单独给药
用生理盐水代替Rho激酶抑制剂溶液，除此之外，用与上述并用给药试验同样的方法进行试验。
4.对照组
用生理盐水代替Rho激酶抑制剂溶液及前列腺素类物质溶液，除此之外，用与上述并用给药试验同样的方法进行试验。
(试验1～4)
各试验中使用的Rho激酶抑制剂溶液、前列腺素类物质溶液以及试验动物在表1中给出。
按照上述(试验方法)以及(给药方法和测定方法)，进行了试验1～4。
表1
  Rho激酶抑制剂溶液   前列腺素类物质溶液   试验动物
 试验1   0.3％化合物A溶液(50μl)   0.06％乌诺前列酮异丙酯溶液(50μl)   家兔(1组4只)
 试验2   1％化合物B溶液(50μl)   0.06％乌诺前列酮异丙酯溶液(50μl)   家兔(1组5只)
 试验3   0.1％化合物A溶液(20μl)   0.005％拉坦前列素溶液(20μl)   食蟹猴(1组3只)
 试验4   1％化合物B溶液(20μl)   0.005％拉坦前列素溶液(20μl)   食蟹猴(1组3只)
(结果及分析)
试验1的结果由图1示出、试验2的结果由图2示出、试验3的结果由图3示出、试验4的结果由图4示出。眼压为从初期眼压开始的变化值。
由图1、图2、图3、图4可以知，Rho激酶抑制剂和前列腺素类物质的并用组比任一药剂单独给药组，即Rho激酶抑制剂给药组或者前列腺素类物质给药组，具有更加良好的眼压降低作用，并且显示出提高上述作用持续性的效果。由此可以确认，通过将Rho激酶抑制剂和前列腺素类物质组合使用可以获得更良好的眼压降低效果和/或提高持续性的效果。
产业实用性
通过将Rho激酶抑制剂和前列腺素类物质组合对眼睛给药，可增强降低眼压的作用和/或提高上述作用的持续性。因此上述组合可有效地作为青光眼治疗剂使用。

Claims (4)

1.一种青光眼治疗剂，由Rho激酶抑制剂与前列腺素类物质组合而成，其中所述Rho激酶抑制剂为(R)-反式-N-(吡啶-4-基)-4-(1-氨基乙基)环己烷羧酰胺、(R)-(+)-N-(1H-吡咯并[2，3-b]吡啶-4-基)-4-(1-氨基乙基)苯酰胺、1-(5-异喹啉磺酰基)高哌嗪、或者1-(5-异喹啉磺酰基)-2-甲基哌嗪，所述前列腺素类物质为乌诺前列酮异丙酯、拉坦前列素、曲伏前列素或者比马前列素。
2.一种青光眼治疗剂，其特征为，是由Rho激酶抑制剂和前列腺素类物质组合而成，二者作用相互补充和/或增强，其中所述Rho激酶抑制剂为(R)-反式-N-(吡啶-4-基)-4-(1-氨基乙基)环己烷羧酰胺、(R)-(+)-N-(1H-吡咯并[2，3-b]吡啶-4-基)-4-(1-氨基乙基)苯酰胺、1-(5-异喹啉磺酰基)高哌嗪、或者1-(5-异喹啉磺酰基)-2-甲基哌嗪，所述前列腺素类物质为乌诺前列酮异丙酯、拉坦前列素、曲伏前列素或者比马前列素。
3.Rho激酶抑制剂和前列腺素类物质的组合在制造青光眼治疗剂中的用途，其中所述Rho激酶抑制剂为(R)-反式-N-(吡啶-4-基)-4-(1-氨基乙基)环己烷羧酰胺、(R)-(+)-N-(1H-吡咯并[2，3-b]吡啶-4-基)-4-(1-氨基乙基)苯酰胺、1-(5-异喹啉磺酰基)高哌嗪、或者1-(5-异喹啉磺酰基)-2-甲基哌嗪，所述前列腺素类物质为乌诺前列酮异丙酯、拉坦前列素、曲伏前列素或者比马前列素。
4.Rho激酶抑制剂和前列腺素类物质的组合在制造青光眼治疗剂中的用途，其特征为，Rho激酶抑制剂和前列腺素类物质的作用相互补充和/或增强，其中所述Rho激酶抑制剂为(R)-反式-N-(吡啶-4-基)-4-(1-氨基乙基)环己烷羧酰胺、(R)-(+)-N-(1H-吡咯并[2，3-b]吡啶-4-基)-4-(1-氨基乙基)苯酰胺、1-(5-异喹啉磺酰基)高哌嗪、或者1-(5-异喹啉磺酰基)-2-甲基哌嗪，所述前列腺素类物质为乌诺前列酮异丙酯、拉坦前列素、曲伏前列素或者比马前列素。
CNB038233029A 2002-08-29 2003-08-29 由Rho激酶抑制剂和前列腺素类物质构成的青光眼治疗剂 Expired - Fee Related CN100425241C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP250223/2002 2002-08-29
JP2002250223 2002-08-29

Publications (2)

Publication Number Publication Date
CN1684689A CN1684689A (zh) 2005-10-19
CN100425241C true CN100425241C (zh) 2008-10-15

Family

ID=31972618

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038233029A Expired - Fee Related CN100425241C (zh) 2002-08-29 2003-08-29 由Rho激酶抑制剂和前列腺素类物质构成的青光眼治疗剂

Country Status (11)

Country Link
US (4) US20050245509A1 (zh)
EP (2) EP1541151B1 (zh)
JP (1) JP5174777B2 (zh)
KR (2) KR101092048B1 (zh)
CN (1) CN100425241C (zh)
AT (1) ATE546143T1 (zh)
AU (1) AU2003257588A1 (zh)
CA (1) CA2496797C (zh)
ES (1) ES2382733T3 (zh)
TW (2) TWI350170B (zh)
WO (1) WO2004019951A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108815169A (zh) * 2018-05-23 2018-11-16 中南大学湘雅医院 一种前列腺素类物质组合得到有效的青光眼治疗剂

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI350170B (en) * 2002-08-29 2011-10-11 Santen Pharmaceutical Co Ltd Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin
WO2004045644A1 (ja) * 2002-11-18 2004-06-03 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
KR101333970B1 (ko) * 2005-05-19 2013-11-27 코와 가부시키가이샤 녹내장 예방 또는 치료제
US8629161B2 (en) * 2005-06-21 2014-01-14 Kowa Co., Ltd. Preventive or remedy for glaucoma
PT1905452E (pt) * 2005-07-12 2013-07-16 Kowa Co Agente para a prevenção ou tratamento do glaucoma
KR101149954B1 (ko) * 2005-08-30 2012-06-01 아사히 가세이 파마 가부시키가이샤 술폰아미드 화합물
US7893050B2 (en) 2005-10-26 2011-02-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
CA2664335C (en) 2006-09-20 2014-12-02 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US8071779B2 (en) * 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8415372B2 (en) 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound
EP2130828A4 (en) 2007-02-28 2010-12-29 Asahi Kasei Pharma Corp sulfonamide
CN101313926B (zh) * 2007-05-30 2012-12-26 中央研究院 转录调控物组合物
ES2396795T3 (es) 2007-07-02 2013-02-27 Asahi Kasei Pharma Corporation Compuesto de sulfonamida y cirstal del mismo
US8410147B2 (en) 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
US8207195B2 (en) 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP3053913B1 (en) 2009-05-01 2018-03-07 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
CA2805242A1 (en) * 2010-07-19 2012-01-26 Inspire Pharmaceuticals, Inc. Bifunctional rho kinase inhibitor compounds, composition and use
JP5822840B2 (ja) 2010-09-30 2015-11-24 ダイトーケミックス株式会社 眼疾患処置薬
TW201235040A (en) * 2011-02-04 2012-09-01 Kowa Co Drug therapy for preventing or treating glaucoma
US9339496B2 (en) 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
WO2014010654A2 (ja) * 2012-07-13 2014-01-16 参天製薬株式会社 スルホンアミド化合物の組み合わせ
CN109528721B (zh) * 2013-03-15 2021-10-01 爱瑞制药公司 联合治疗
KR102307281B1 (ko) 2013-10-31 2021-09-29 알레간 인코포레이티드 프로스타마이드-함유 안구내 삽입물 및 그것의 사용 방법
KR20150090445A (ko) 2014-01-29 2015-08-06 주식회사 이노칩테크놀로지 적층칩 소자
CA2970254A1 (en) * 2014-12-12 2016-06-16 Kowa Company, Ltd. Composition
GB2556500A (en) * 2015-05-29 2018-05-30 Edge Therapeutics Inc Compositions and methods for reducing visual loss
KR102579582B1 (ko) 2015-11-17 2023-09-15 에어리 파마슈티컬즈, 인코포레이티드 키나아제 억제제 및 이의 중간체의 제조 방법
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
CA3035566A1 (en) 2016-08-31 2018-03-08 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
CN110506037A (zh) 2017-03-31 2019-11-26 爱瑞制药公司 芳基环丙基-氨基-异喹啉酰胺化合物
CN111479568A (zh) * 2017-12-21 2020-07-31 参天制药株式会社 司培前列素与Rho激酶抑制剂的组合药物
KR20200103041A (ko) 2017-12-21 2020-09-01 산텐 세이야꾸 가부시키가이샤 오미데네팍의 조합
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2021182596A1 (ja) * 2020-03-13 2021-09-16 興和株式会社 上眼瞼溝深化改善剤

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0286903A1 (en) * 1987-04-03 1988-10-19 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
EP0308135A2 (en) * 1987-09-18 1989-03-22 R-Tech Ueno Ltd. Ocular hypotensive agents
WO1990002553A1 (en) * 1988-09-06 1990-03-22 Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
WO1994006433A1 (en) * 1992-09-21 1994-03-31 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
EP0639563A2 (en) * 1993-08-03 1995-02-22 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their analogues for the manufacture of a medicament for the treatment of glaucoma and ocular hypertension
WO1997023222A1 (en) * 1995-12-21 1997-07-03 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
WO1998006433A1 (fr) * 1996-08-12 1998-02-19 Yoshitomi Pharmaceutical Industries, Ltd. MEDICAMENTS COMPRENANT UN INHIBITEUR DE LA Rho KINASE
WO2000009162A1 (fr) * 1998-08-17 2000-02-24 Senju Pharmaceutical Co., Ltd. Medicaments preventifs/curatifs pour le glaucome

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2945008C2 (de) * 1979-11-08 1981-08-20 Lück, Werner, 4290 Bocholt Stützelement für medizinische Lagerungszwecke
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4952581A (en) * 1987-04-03 1990-08-28 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
CA1334168C (en) * 1988-04-26 1995-01-31 Louis M. De Santis Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers
JPH02108U (zh) 1988-06-14 1990-01-05
ES2314786T3 (es) * 1998-04-02 2009-03-16 Genentech, Inc. Uso de interferon gamma para el tratamiento de la hipertrofia cardiaca.
JP4212149B2 (ja) 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
SE9803761D0 (sv) * 1998-11-04 1998-11-04 Synphora Ab Method to avoid increased iridial pigmentation during prostaglandin treatment
AU3328600A (en) * 1999-03-25 2000-10-16 Santen Pharmaceutical Co. Ltd. Ocular tension-lowering agents
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AR035541A1 (es) 2000-11-13 2004-06-16 Pharmacia Ab Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio
DE60211317T2 (de) 2001-03-23 2007-04-12 Bayer Corp. Rho-kinase inhibitoren
PT1370552E (pt) 2001-03-23 2007-04-30 Bayer Pharmaceuticals Corp Inibidores de rho-quinase
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma INHIBITORS OF RHO KINASE
US7015210B2 (en) * 2001-12-12 2006-03-21 Pharmacia Corporation Methods of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
TWI350170B (en) * 2002-08-29 2011-10-11 Santen Pharmaceutical Co Ltd Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin
WO2004045644A1 (ja) * 2002-11-18 2004-06-03 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
WO2004105757A2 (en) * 2003-05-29 2004-12-09 Schering Aktiengesellschaft Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0286903A1 (en) * 1987-04-03 1988-10-19 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
EP0308135A2 (en) * 1987-09-18 1989-03-22 R-Tech Ueno Ltd. Ocular hypotensive agents
WO1990002553A1 (en) * 1988-09-06 1990-03-22 Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
WO1994006433A1 (en) * 1992-09-21 1994-03-31 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
EP0639563A2 (en) * 1993-08-03 1995-02-22 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their analogues for the manufacture of a medicament for the treatment of glaucoma and ocular hypertension
WO1997023222A1 (en) * 1995-12-21 1997-07-03 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
WO1998006433A1 (fr) * 1996-08-12 1998-02-19 Yoshitomi Pharmaceutical Industries, Ltd. MEDICAMENTS COMPRENANT UN INHIBITEUR DE LA Rho KINASE
WO2000009162A1 (fr) * 1998-08-17 2000-02-24 Senju Pharmaceutical Co., Ltd. Medicaments preventifs/curatifs pour le glaucome

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108815169A (zh) * 2018-05-23 2018-11-16 中南大学湘雅医院 一种前列腺素类物质组合得到有效的青光眼治疗剂

Also Published As

Publication number Publication date
KR20110004920A (ko) 2011-01-14
KR101092048B1 (ko) 2011-12-12
JP2009298808A (ja) 2009-12-24
US20100041671A1 (en) 2010-02-18
US20120040994A1 (en) 2012-02-16
EP1541151A4 (en) 2007-07-18
WO2004019951A1 (ja) 2004-03-11
CA2496797C (en) 2012-01-10
US20100063060A1 (en) 2010-03-11
EP1541151A1 (en) 2005-06-15
CA2496797A1 (en) 2004-03-11
TWI337881B (en) 2011-03-01
EP2314299A1 (en) 2011-04-27
KR101160780B1 (ko) 2012-06-27
JP5174777B2 (ja) 2013-04-03
TW201032807A (en) 2010-09-16
CN1684689A (zh) 2005-10-19
US20050245509A1 (en) 2005-11-03
ATE546143T1 (de) 2012-03-15
TW200409654A (en) 2004-06-16
TWI350170B (en) 2011-10-11
ES2382733T3 (es) 2012-06-13
KR20050057014A (ko) 2005-06-16
EP1541151B1 (en) 2012-02-22
AU2003257588A1 (en) 2004-03-19

Similar Documents

Publication Publication Date Title
CN100425241C (zh) 由Rho激酶抑制剂和前列腺素类物质构成的青光眼治疗剂
CN101198354B (zh) 青光眼的预防或治疗剂
US20110263638A1 (en) Therapeutic agent for glaucoma comprising rho kinase inhibitor and ß- blocker
CN101198355B (zh) 预防或治疗青光眼的药剂
CN105902551A (zh) 用于预防或治疗青光眼的药物疗法
JP4482726B2 (ja) Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
ES2210018T3 (es) Antagonistas de 5ht-2 para regular la presion intraocular y tratar el glaucoma.
WO2019131901A1 (ja) ピリジルアミノ酢酸化合物を含有する医薬製剤
CN100496500C (zh) 含布那唑嗪和前列腺素的青光眼治疗剂
CN1864688B (zh) 青光眼的预防或治疗剂
EP3730137A1 (en) Therapeutic agent for glaucoma comprising fp agonist and blocker
JP2018083778A (ja) 濾過胞を維持するための組成物
CN101500558A (zh) 用作降眼压制剂的琥珀酰亚胺衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081015

Termination date: 20190829

CF01 Termination of patent right due to non-payment of annual fee